Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo?
|
|
- Claud Carson
- 6 years ago
- Views:
Transcription
1 Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo? Prof. Massimo Salvetti Clinica Medica University of Brescia
2 Percieved risk
3 Actual risk
4 Sehestedt et al, European Heart Journal 2010 Risk prediction is improved by adding markers of sublinical organ damage to SCORE
5 Stratification of total CV risk Further emphasis has been given to identification of organ damage, since hypertension-related asymptomatic alterations in several organs indicate progression in the CVD continuum, which markedly increases the risk beyond that caused by the simple presence of risk factors 2013 ESH/ESC Guidelines for the management of arterial hypertension
6 Evaluation of the elderly patient with known or suspected hypertension must accurately determine BP, and if elevated: 1) identify reversible and/or treatable causes; 2) evaluate for organ damage; 3) assess for other CVD risk factors/comorbid conditions affecting prognosis; and 4) identify barriers to treatment adherence. JACC 2014
7 Journal of Hypertension 2010 * p< Low * Moderate * * High * Routine + echocardiography + renal TOD + PWV + carotid ultrasound
8 Factors - other than office BP - influencing prognosis used for stratification of total CV risk (2) 2013 ESH/ESC Guidelines for the management of arterial hypertension
9 Search for asymptomatic organ damage - Kidney 2013 ESH/ESC Guidelines for the management of arterial hypertension
10 (incidence rate ratio) Hunt II Study, Arch Intern Med participants of the second Nord-Trøndelag Health Study (HUNT II), a Norwegian community-based health study, followed for 8.3 years with a 71% participation rate Cardiovascular mortality risk
11 The combined variable improved cardiovascular risk stratification at all age levels, but particularly in elderly persons where the predictive power of traditional risk factors is attenuated... Arch Intern Med. 2007
12 European Heart Journal 2007 Prospective study of 70-year-old men free from HF at baseline (Uppsala Longitudinal Study of Adult Men coho Cutoff: UAER median value, 4.7 mg/min In Cox proportional hazards models adjusted for established and novel risk factors for HF, a 1 SD increase in log UAER increased the risk of HF in individuals without anti hypertensive treatment (hazard ratio 1.49; 95% CI ; p < 0.005)
13 Search for asymptomatic organ damage - Arteries 2013 ESH/ESC Guidelines for the management of arterial hypertension
14 A man is as old as his arteries Thomas Sydenham,
15 Mannheim Carotid Intima-Media Thickness Consensus Update ( ) Cerebrovascular Disease 2007; ;23:75 80 plaque and IMT measurement according to Mannheim consensus. 1: thickness > 1.5 mm 2: lumen encroaching > 0.5 mm; 3, 4: > 50% of the surrounding IMT value
16 Unadjusted Cumulative Event-free Rates for the Combined End Point of Myocardial Infarction or Stroke, According to Quintile of Combined Intima-Media Thickness 5858 subjects 65 years of age or older, follow-up period of 6.2 years NEJM 1999, D.H. O Leary et al.
17 1289 men aged 60 to 74 years without a previous stroke or CHD Incidence of stroke Men with a plaque in the ICA had a 3-fold higher risk of stroke than those without The combination a plaque, of CCA and internal the carotid plaque artery (ICA) surface wall thickness irregularity was a further better predictor of the risk of stroke than was CCA wall thickness alone. increased the stroke risk. A significant excess risk of stroke was confined to men with an uncalcified plaque. Stroke 2004
18 DBP (mm Hg) DBP (mm Hg) SBP (mm Hg) SBP (mm Hg) DBP (mm Hg) DBP (mm Hg) SBP (mm Hg) SBP (mm Hg) Mean Systolic and Diastolic BP by Age and Race/Ethnicity for Men and Women (US Population ³Age 18 Years, NHANES III) Non-Hispanic Black Non-Hispanic White Mexican American Pulse pressure 110 Pulse pressure Men, Age (y) Women, Age (y) Burt VI, et al. Hypertension. 1995;25:
19 Compliance function of large arteries Arterial compliance Arterial compliance Left Ventricl e Peripheral resistances Left Ventricl e Peripheral resistances SYSTOLE DIASTOLE
20 Compliance function of large arteries Arterial compliance Arterial compliance Left Ventricl e Peripheral resistances Left Ventricl e Peripheral resistances SYSTOLE DIASTOLE
21 Carotid-femoral pulse wave velocity DL dp PWV. Dt. V dv Dt L Carotid femoral PWV can be assimilated to aortic stiffness
22 Reference values for pulse wave velocity (PWV): mean values according to age and blood pressure categories ( subjects) Reference Values for Arterial Stiffness' Collaboration. Eur Heart J 2010;31:
23 A cohort of 141 subjects (mean age, 87.1±6.6 years), dementia in 63.8 %, was studied in 3 geriatrics departments in a Paris suburb. During the 30-month follow-up, 56 patients died (27 from CV events). Logistic regressions indicated that age (p=0.005) and a loss of autonomy (p=0.01) were the best predictors of overall mortality. For cardiovascular mortality, aortic PWV was the major risk predictor (P0.016). Arterioscler Thromb Vasc Biol. 2001
24 Reclassification indices showed that the addition of apwv improved risk prediction (13% for 10-year CVD risk for intermediate risk). Ben Shlomo B et al, JACC 2014
25 Ben Shlomo et al, JACC 2014
26 280 eighty older subjects with subjective complaints of memory loss and no previous stroke (age 78.3±6.3 yrs) Interpretation: Systemic hemodynamic parameters (higher PWV and hypotension) together with cerebral microvascular damage (WML) are significantly associated with poorer cognitive function and may identify older subjects with subjective complaints of memory loss at higher risk of cognitive decline. International Journal of Cardiology 2013
27 Hypertension 2013; 61:
28 Hypertension 2014
29 Correlation between PWV and LV structure Studio Vobarno, Clinica Medica, Università di Brescia
30
31 Search for asymptomatic organ damage - Heart 2013 ESH/ESC Guidelines for the management of arterial hypertension
32 Increase in wall thickness with age in healthy men and women Bronx Longitudinal Study Aging Prevalence of concentric LV geometry increases with agenormalized RWT Values age-normalized RWTm = 0.41 RWTp = 0.40 Gerstenblith G et al. Circulation. 1977;56: de Simone G et al Hypertension. 2005;45:64-68
33 Prevalenza Disfunzione Diastolica (Criteri Primari) 60 % 50 p < p = p = p = p < Tutti M F C NC No Sì Controllo PA Sindrome Metabolica > > > 80 < Età PAS Zanchetti et al., J Hypertens 2007; 25:
34 LVH and CV Risk in Different Populations LVH diagnosed by echocardiography is a powerful predictor of myocardial infarction, stroke and CV death in: Apparently uncomplicated hypertensive patients In subjects with or without angiographic coronary heart disease In patients with previous myocardial infarction In subjects from general populations in epidemiological studies It has been estimated that 1g/m2 increase in LVMI is associated with a 1-2 % increase in the risk of CV events
35 Myocytes Cardiomyocite changes Hypertrophy Cell loss (apoptosis) Functional changes Systolic Dysfunction Pressure Overload Extracellular matrix Collagen network changes Reactive fibrosis Replacement fibrosis HF 26/01/ :09:55 Vascular Compartment Coronary disease Microcirculation changes Capillary rarefaction Diastolic Dysfunction
36 LV mass and incident heart failure The Cardiovascular Health Study Quartiles of echocardiographic LVM/BSA (g/m2): < 67.7, 67.8 to 79.2, 79.3 to 93.5, and > Drazner et al. JACC 2004; 43 :
37 In multivariable logistic regression models, including age, sex, BP levels, and use of antihypertensive drugs as covariates, the highest LVMI was found to be independently associated with a two-fold higher likelihood of having dementia. The association persisted significant even after adjustment for arterial stiffness
38 Sensitivity to detect treatment-induced changes, time to change and prognostic value of change by markers of asymptomatic OD 2013 ESH/ESC Guidelines for the management of arterial hypertension
39 VOBARNO Study 478 subjects (age range years) 40% elderly (193 subjects) % Prevalence of hypertension 53 Non elderly Χ 2 < Elderly Clinica Medica, University of Brescia % % Uncontrolled hypertension Χ 2 < Non elderly Elderly Resistant hypertension Χ 2 < Non elderly Elderly
40 Prevalence of OD 35 Prevalence of LVH % , ,1 Non elderly Elderly Studio Vobarno, Clinica Medica, Università di Brescia
41 Prevalence of OD Prevalence of IMT or plaques Prevalence of PWV>10 m/s % ,2 Non elderly 95,9 Elderly % ,1 Non elderly 68,5 Elderly Studio Vobarno, Clinica Medica, Università di Brescia
42 Grazie per l attenzione
43
44 8.4: Continued search for asymptomatic organ damage On the whole, it appears reasonable to search for at least some asymptomatic OD, not only for the initial stratification of CV risk, but also during follow-up 2013 ESH/ESC Guidelines for the management of arterial hypertension
45 0 BB VS OTHER DRUGS 31 paired comparisons 2680 pts 0 ARB VS OTHER DRUGS 20 paired comparisons 2384 pts BB -8,8 Other drugs * -11, * -12,6-9,4 ARB Other drugs * p<0.01 Pairwise Comparison of Each Drug Class With the Other Classes Statistically Combined Fagard et al, Hypertension 2009
46 Treatment Age Years Treatment Duration N pts Change in LVM % Change in SBP mmhg Terpstra W et al 2000 ELVERA Lisinopril years % -26 Amlodipine % Schulman S et al 1990 Verapamil > 60 years 6 months % -28 atenolol % -32 Dahlof et al 2004 LIFE Losartan years 6 months % -30 Mean age Atenolol % yrs
47 Comparative effect of antihypertensive drugs on aortic stiffness, wave reflection and central PP Aortic PWV Central PP, Augmentation index ACE-Inhibitors Angiotensin Receptor Blockers Calcium channel blockers Thiazide diuretics Vasodilating β-blockers Non vasodilating β-blockers
48 22 trials published between 1996 and 2005: - 8 trials antihypertensive drugs vs placebo or no-treatment - 9 trials new with old drug classes - 5 trials ACE inhibitors and CCBs Conclusions: Calcium channel blockers reduce carotid intima-media thickening. This mechanism might contribute to their superior protection against stroke. Stroke online June 8, 2006
49
When should you treat blood pressure in the young?
ESC Stockholm - Dilemmas in Cardiovascular Disease Prevention in the Young: 30 th August 2010 When should you treat blood pressure in the young? Bryan Williams MD FRCP FAHA FESC Professor of Medicine Department
More informationCentral Pressures and Prehypertension
Central Pressures and Prehypertension Charalambos Vlachopoulos Associate Professor of Cardiology 1 st Cardiology Dept Athens Medical School Central Pressures and Prehypertension Charalambos Vlachopoulos
More informationHow clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
More informationΗ σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις
Η σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις Ελένη Τριανταφυλλίδη Επιμελήτρια Α Β Πανεπιστημιακή Καρδιολογική Κλινική Αττικό Νοσοκομείο
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationArterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly. Piotr Jankowski
Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly Piotr Jankowski I Department of Cardiology and Hypertension CM UJ, Kraków, Poland piotrjankowski@interia.pl Vienna,
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationEarly Detection of Damaged Organ
Early Detection of Damaged Organ Regional Cardiovascular Center, Chungbuk National University Kyung-Kuk Hwang Contents NICE guideline 2011 - Confirm the diagnosis of HT ambulatory blood pressure monitoring
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationEffects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France
Effects of Renin-Angiotensin System blockade on arterial stiffness and function Gérard M. LONDON Manhès Hospital Paris, France Determinants of vascular overload (afterload) on the heart Peripheral Resistance
More informationDirector of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016
The differential effect of Atherosclerosis on end organ damage in adult and elderly patients with CVRF: New Algorithm for Hypertension Diagnosis and Treatment R. Zimlichman, FAHA, FASH, FESC, FESH Chief
More informationBackground. Metabolic syndrome T2DM CARDIOVASCULAR DISEASE. Major Unmet Clinical Need. Novel Risk Factors. Classical Risk Factors LDL-C.
The effect of metabolic syndrome for left ventricular geometry, arterial stiffness and carotid intima-media thickness in Korean general population Result from Atherosclerosis RIsk of Rural Area in Korea
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationArterial Pressure in CKD5 - ESRD Population Gérard M. London
Arterial Pressure in CKD5 - ESRD Population Gérard M. London INSERM U970 Paris 150 SBP & DBP by Age, Ethnicity &Gender (US Population Age 18 Years, NHANES III) 150 SBP (mm Hg) 130 110 80 Non-Hispanic Black
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationTHE HEART AND HYPERTENSION. Philippe Gosse Hypertension Unit University Hospital Bordeaux
THE HEART AND HYPERTENSION Philippe Gosse Hypertension Unit University Hospital Bordeaux INCREASED LVM Cardiomyocytes hypertrophy is a response to pressure overload This response is influenced by many
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More informationThe monthly ESH guide through publications
NEWSLETTER APRIL 2016 The monthly ESH guide through publications Edited by: Prof Costas Tsioufis, ESH Secretary and Dr Alex Kasiakogias Effects of hypertension treatment on heart failure: insights from
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationArterial function and longevity Focus on the aorta
Arterial function and longevity Focus on the aorta Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Secrets of longevity Secrets of longevity Unveiling
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationHypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationAssessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time. Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France
Assessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France The causes of Cardiovascular Diseases in CKD Systolic BP;
More informationEndothelial function is impaired in women who had pre-eclampsia
Endothelial function is impaired in women who had pre-eclampsia Christian Delles, Catriona E Brown, Joanne Flynn, David M Carty Institute of Cardiovascular and Medical Sciences University of Glasgow United
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationINTERNATIONAL REGISTRY FOR AMBULATORY BLOOD PRESSURE AND ARTERIAL STIFFNESS TELEMONITORING
INTERNATIONAL REGISTRY FOR AMBULATORY BLOOD PRESSURE AND ARTERIAL STIFFNESS TELEMONITORING VASOTENS Registry Vascular health ASsessment Of The hypertensive patients Project Coordinator: Dr. Stefano Omboni
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More information47 Hypertension in Elderly
47 Hypertension in Elderly YOU DO NOT HEAL OLD AGE; YOU PROTECT IT; YOU PROMOTE IT; YOU EXTEND IT Sir James Sterling Ross Abstract: The prevalence of hypertension rises with age and the complications secondary
More informationHypertension in Aortic Valve Disease
Hypertension in Aortic Valve Disease Hanna M. Nosseir MRCP, FRCP Head of Cardiology department Galaa Military Medical Complex Aortic stenosis: Introduction Arterial hypertension and aortic stenosis are
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationAn Epidemiological Overview
An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationPreventing Early Vascular Ageing (EVA) and its hemodynamic changes
Translational Research 31 st October 2013, Moscow Preventing Early Vascular Ageing (EVA) and its hemodynamic changes Peter M Nilsson, MD, PhD Department of Clinical Sciences Lund University University
More informationIncidental Findings; Management of patients presenting with high BP. Phil Swales
Incidental Findings; Management of patients presenting with high BP Phil Swales Consultant Physician Acute & General Medicine University Hospitals of Leicester NHS Trust Objectives The approach to an incidental
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationD Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis, E Christoforatou, A Samentzas, A Siama, C Stefanadis
Peripheral Vessels Unit, 1st Department of Cardiology Athens Medical School Hippokration Hospital, Athens, Greece D Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis,
More informationClinical application of Arterial stiffness. pulse wave analysis pulse wave velocity
Clinical application of Arterial stiffness pulse wave analysis pulse wave velocity Arterial system 1. Large arteries: elastic arteries Aorta, carotid, iliac, Buffering reserve: store blood during systole
More informationALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status
ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationPharmacological modulation of vascular structure and function. L. Van Bortel. Heymans Institute of Pharmacology, Ghent University
Pharmacological modulation of vascular structure and function L. Van Bortel Heymans Institute of Pharmacology, Ghent University BHC 2015 Pharmacological modulation of Endothelial function CIMT Pulse wave
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationIndividual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki
Individual management of arterial hypertension Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki From Population to Individual Management of Arterial Hypertension Epidemiologic impact
More informationAllopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease
Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease Michelle P Kao, Donald S Ang, Steve Gandy, Chim C Lang, Allan D Struthers Division of
More informationCauses of Poor BP control Rates
Goals Of Hypertension Management in Clinical Practice World Hypertension League (WHL) Meeting Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular
More informationWhich method is better to measure arterial stiffness; augmentation index, pulse wave velocity, carotid distensibility? 전북의대내과 김원호
Which method is better to measure arterial stiffness; augmentation index, pulse wave velocity, carotid distensibility? 전북의대내과 김원호 Arterial stiffness Arterial stiffness is inversely related to arterial
More informationCoronary artery disease (CAD) risk factors
Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationAn Epidemiological Overview
An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in
More informationReview of Cardiac Imaging Modalities in the Renal Patient. George Youssef
Review of Cardiac Imaging Modalities in the Renal Patient George Youssef ECHO Left ventricular hypertrophy (LVH) assessment Diastolic dysfunction Stress ECHO Cardiac CT angiography Echocardiography - positives
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationHypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?
Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular
More informationHypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
More informationFalls Assessment and Medication
Falls Assessment and Medication Professor T.Masud President-Elect British Geriatrics Society Nottingham University Hospitals NHS Trust, UK Visiting Professor University of Southern Denmark Mrs GH is a
More informationVALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION
VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationCan Anti-hypertension Therapy Reverse Vascular Aging and Dementia?
2012. 4. 20-21 춘계심장학회 _ 부산 Can Anti-hypertension Therapy Reverse Vascular Aging and Dementia? Jeong Bae Park, MD, PhD Cardiology, Cheil General Hospital, Kwandong University, Seoul, Korea The Pulse : revived
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationAbstract nr AHA, Chicago November European Heart Journal Cardiovascular Imaging, in press. Nr Peter Blomstrand
Left Ventricular Diastolic Function Assessed by Echocardiography and Tissue Doppler Imaging is a strong Predictor of Cardiovascular Events in Patients with Diabetes Mellitus Type 2 Peter Blomstrand, Martin
More informationHypertension Management Focus on new RAAS blocker. Disclosure
Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationImproving risk prediction focusing on intermediate endpoints. Arterial stiffness. Pr. Stéphane LAURENT, MD, PhD, FESC
Improving risk prediction focusing on intermediate endpoints Arterial stiffness Pr. Stéphane LAURENT, MD, PhD, FESC Pharmacology Department, Hôpital Européen Georges Pompidou, Paris Cardiovascular Research
More informationTheoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D.
Theoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D. TensioMed Arterial Stiffness Centre, Budapest Heart Institute, Faculty of Medicine, University of Pécs
More informationEstimated Pulse Wave Velocity Calculated from Age and Mean Arterial Blood Pressure
Received: August 19, 2016 Accepted after revision: November 4, 2016 Published online: December 1, 2016 2235 8676/16/0044 0175$39.50/0 Mini-Review Estimated Pulse Wave Velocity Calculated from Age and Mean
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationHow do we diagnose hypertension today? Presentation Subtitle
How do we diagnose hypertension today? Presentation Subtitle Renata Cífková Case 1 JM, a 64-year-old lady referred to our center because of undesirable effects of her antihypertensive medication Personal
More informationUnderstanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?
Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,
More informationWhich CVS risk reduction strategy fits better to carotid US findings?
Which CVS risk reduction strategy fits better to carotid US findings? Dougalis A, Soulaidopoulos S, Cholongitas E, Chalevas P, Vettas Ch, Doumtsis P, Vaitsi K, Diavasti M, Mandala E, Garyfallos A 4th Department
More informationDr. Khan Abul Kalam Azad Associate Professor Department of Medicine SZRMC, Bogra
Dr. Khan Abul Kalam Azad Associate Professor Department of Medicine SZRMC, Bogra Beta-blockers were used in several longterm morbidity and trials in the treatment of hypertension, either alone or in comparison
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More information